| Company Name | Pfizer Limited |
|---|---|
| Protocol Number | C4671061 |
| Title of Study | Real world evaluation of COVID-19 burden and nirmatrelvir/ritonavir in Taiwan using National Health Insurance Research Database |
| Primary Objective | This study aims to evaluate large national database systems in Taiwan, to establish the patient profile and to evaluate the utilization and outcomes associated with nirmatrelvir/ritonavir and the impact on long COVID-19. |
| Number of Sites | NA |
| Period of Study | From：09/01/2023 to：12/31/2024 |
| Number of Patients | NA人 |
| IRB Approval Date | 16/10/2023 |
| Publication Plan / Date | Unknown |
